Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy

Andrea Necchi, Gregory R. Pond, Patrizia Giannatempo, Giuseppe Di Lorenzo, Bernhard J. Eigl, Jenn Locke, Sumanta K. Pal, Neeraj Agarwal, Austin Poole, Ulka N. Vaishampayan, Guenter Niegisch, Syed A. Hussain, Parminder Singh, Joaquim Bellmunt, Guru Sonpavde

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Background Outcomes with cisplatin-based first-line therapy for advanced UC after previous perioperative cisplatin-based chemotherapy are unclear. In this study we evaluated outcomes with a focus on the effect of time from previous cisplatin-based perioperative chemotherapy. Patients and Methods Data were collected for patients who received cisplatin-based first-line therapy for advanced UC after previous perioperative cisplatin-based therapy. Cox proportional hazards models were used to investigate the prognostic ability of visceral metastasis, ECOG PS, TFPC, anemia, leukocytosis, and albumin on overall survival (OS). Results Data were available for 41 patients from 8 institutions including 31 men (75.6%). The median age was 61 (range, 41-77) years, most received gemcitabine plus cisplatin (n = 26; 63.4%), and the median number of cycles was 4 (range, 1-8). The median OS was 68 weeks (95% confidence interval [CI], 48.0-81.0). Multivariable Cox regression analysis results showed an independent prognostic effect on OS for PS > 0 versus 0 (hazard ratio [HR], 4.56 [95% CI, 1.66-12.52]; P =.003) and TFPC ≥ 78 weeks versus < 78 weeks (HR, 0.48 [95% CI, 0.21-1.07]; P =.072). The prognostic model for OS was internally validated with c-index = 0.68. Patients with TFPC < 52 weeks, 52 to 104 weeks, and ≥ 104 weeks had median survival of 42, 70, and 162 weeks, respectively. Conclusion Longer TFPC ≥ 78 weeks and ECOG PS = 0 were independently prognostic for better survival with cisplatin-based first-line chemotherapy for advanced UC after previous perioperative cisplatin-based chemotherapy. The data support using TFPC ≥ 52 weeks to rechallenge with cisplatin-based first-line chemotherapy for metastatic disease.

Original languageEnglish (US)
Pages (from-to)178-184
Number of pages7
JournalClinical Genitourinary Cancer
Volume13
Issue number2
DOIs
StatePublished - Apr 1 2015

Keywords

  • Cisplatin
  • First-line
  • Peri-operative
  • Urothelial carcinoma

ASJC Scopus subject areas

  • Oncology
  • Urology

Fingerprint Dive into the research topics of 'Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy'. Together they form a unique fingerprint.

  • Cite this

    Necchi, A., Pond, G. R., Giannatempo, P., Di Lorenzo, G., Eigl, B. J., Locke, J., Pal, S. K., Agarwal, N., Poole, A., Vaishampayan, U. N., Niegisch, G., Hussain, S. A., Singh, P., Bellmunt, J., & Sonpavde, G. (2015). Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy. Clinical Genitourinary Cancer, 13(2), 178-184. https://doi.org/10.1016/j.clgc.2014.08.010